X4 Pharmaceuticals, Inc. (XFOR)

NCM – Real Time Price. Currency in USD

4.49

+0.20 (4.79%)

Market open: Aug 12, 2026, 1:05 PM EDT

4.28

0.00 (0.00%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

07.08.2026

X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates

X4 Pharmaceuticals (XFOR) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $3.47 per share a year ago.

06.08.2026

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today reported financial results for the second quarter ended June 30, 2026 and provided a corporate update.

03.08.2026

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on July 31, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 12,000 shares of X4's common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4's Compensation Committee of the Board of Directors.

Videos

No Data

There is no data to display

Press releases

06.08.2026

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

03.08.2026

X4 Pharmaceuticals, Inc. (XFOR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

X4 Pharmaceuticals, Inc. (XFOR)

X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Videos

No Data

Press releases

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Videos

No Data

Press releases

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Search stocks

X4 Pharmaceuticals, Inc. (XFOR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

X4 Pharmaceuticals, Inc. (XFOR)

X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Videos

No Data

Press releases

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Videos

No Data

Press releases

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)